- Home
- PCLA vs PULM Comparison
PCLA vs PULM Comparison
Compare PCLA & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCLA
- PULM
- Stock Information
- Founded
- PCLA 2008
- PULM 2003
- Country
- PCLA Japan
- PULM United States
- Employees
- PCLA N/A
- PULM N/A
- Industry
- PCLA Building Products
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- PCLA Consumer Discretionary
- PULM Health Care
- Exchange
- PCLA Nasdaq
- PULM Nasdaq
- Market Cap
- PCLA 71.3M
- PULM 33.2M
- IPO Year
- PCLA 2025
- PULM N/A
- Fundamental
- Price
- PCLA $3.25
- PULM $6.38
- Analyst Decision
- PCLA
- PULM
- Analyst Count
- PCLA 0
- PULM 0
- Target Price
- PCLA N/A
- PULM N/A
- AVG Volume (30 Days)
- PCLA 2.4M
- PULM 59.3K
- Earning Date
- PCLA 01-01-0001
- PULM 08-12-2025
- Dividend Yield
- PCLA N/A
- PULM N/A
- EPS Growth
- PCLA N/A
- PULM N/A
- EPS
- PCLA N/A
- PULM N/A
- Revenue
- PCLA $5,475,228.00
- PULM $1,921,000.00
- Revenue This Year
- PCLA N/A
- PULM N/A
- Revenue Next Year
- PCLA N/A
- PULM $134.88
- P/E Ratio
- PCLA N/A
- PULM N/A
- Revenue Growth
- PCLA 40.19
- PULM N/A
- 52 Week Low
- PCLA $0.37
- PULM $1.78
- 52 Week High
- PCLA $9.80
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- PCLA N/A
- PULM 39.53
- Support Level
- PCLA N/A
- PULM $6.26
- Resistance Level
- PCLA N/A
- PULM $6.96
- Average True Range (ATR)
- PCLA 0.00
- PULM 0.85
- MACD
- PCLA 0.00
- PULM -0.11
- Stochastic Oscillator
- PCLA 0.00
- PULM 39.71
About PCLA PicoCELA Inc. American Depositary Shares
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).